Skip Navigation

Journal of Tropical Pediatrics 1996 42(5):262-266; doi:10.1093/tropej/42.5.262
© 1996 by Oxford University Press
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Çetingül, N.
Right arrow Articles by Yagci, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Çetingül, N.
Right arrow Articles by Yagci, R.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

research-article

Alpha-Interferon-2b Treatment for Chronic Hepatitis-B Infection in Children with Cancer

Nazan Çetingül, MD*, Kaan Kavakli, MD*, Canan Vergin, MD*, Senay Öztop, MD*, Güngör Nisli, MD*, Sema Aydogdu, MD**, Tijen Özacar, MD***, Altinay Bilgiç, MD***, Gül Yüce, MD{dagger} and Rasit Yagci, MD**

*Department of Pediatric Hematology-Oncology, Ege University, Faculty of Medicine Bornova, Izmir 35100, Turkey
**Department of Pediatric Gastroenterology, Ege University, Faculty of Medicine Bornova, Izmir 35100, Turkey
***Department of Microbiology, Ege University, Faculty of Medicine Bornova, Izmir 35100, Turkey
{dagger}Department of Pathology, Ege University, Faculty of Medicine Bornova, Izmir 35100, Turkey

We have evaluated the efficacy of treatment with recombinant Interferon-2b (IFN-2b) in 12 children with cancer who developed chronic hepatitis-B infection. Seven of them had lymphoblastic leukaemia and others had solid tumours. Seven cases were male. Mean age was 10.5 years with a range of 5–16 years. Chronic Hepatitis B was diagnosed biochemically, serologically and histopathologically. They were HBsAg(+), HBV-DNA(+), and HCV(–), HIV(–). Seven cases were HBeAg(+) and two of them were anti-Delta IgG{+). Liver biopsy revealed chronic active hepatitis in six cases and persistent hepatitis in three cases. IFN was given at the dose of 5 MU/m2 three times a week, subcutaneously for 6 months. It was well tolerated. After IFN therapy, ALT levels returned to normal in seven cases. All cases were still HBsAg(+). Four of them seroconverted to anti-HBe antibody. Loss of serum HBV-DNA in three cases, but 11 cases showed a marked decrease after IFN. The control liver biopsies showed that histopathological activity index was diminished in five cases. Other 16 patients, serving as control, received no therapy. Five of them were leukaemia and others were solid tumours. Twelve cases were male. Mean age was 9.3 years with a range of 4–19 years. After 6 months, only one patient lost HBV-DNA and three of them seroconverted to anti-HBe with normalization of ALT values.

In our study, IFN treatment favourably influenced the progress of chronic hepatitis B in children with cancer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.